Allogene Therapeutics. Every tracked FinTwit mention of $ALLO, newest first. 18 mentions since the first on Aug 4, 2025. See the price chart.
April 2026 · 15 mentions
Apr 15
Jacob Plieth — Why $RVMD & $ALLO are a microcosm of biotech's historic struggle for success. Some musings from me on @ApexOnco -> https://t.co/3lWgzQplvc↗
Jacob Plieth — @Sanctuary_Bio @Michaelrose102 $ALLO offering coming like night follows day https://t.co/s7IZv5bSHz↗
Apr 13
Jacob Plieth — Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8↗
Apr 13
Jacob Plieth — Alpha-3 exactly in line with $ALLO expectations: 7/12 cema-cel patients went MRD-ve, versus 2/12 "spontaneous" clearances for observation alone. Now to repeat this in 220 patients,…↗
Adam Feuerstein ✡️ — Allogene $ALLO cema-cel interim ALPHA3 results just reported:
B-cell lymphoma MRD negativity: cema-cel 58% vs observation 16%
A 42% absolute difference in MRD clearance is bett…↗
Jacob Plieth — Key $ALLO catalyst coming pre market today, with first data from cema-cel's Alpha-3 study in DLBCL consolidation. What to look for: https://t.co/a19BVEppqP↗
Apr 10
Jacob Plieth — This is getting quite tiresome: first $ORIC, now $ALLO & $IDYA. Why are you sitting on market-sensitive data rather than releasing it now? https://t.co/N8q95re7ho↗
Apr 10
Adam Feuerstein ✡️ — My $ALLO preview if you want some background
https://t.co/tcPFelUH3C↗
Adam Feuerstein ✡️ — This week's Biotech Scorecard: Allogene $ALLO: A preview of its April interim analysis. Very interesting (to me, at least)
There just might be a path forward for off-the-shelf CAR…↗
November 2025 · 1 mention
Nov 3
Jacob Plieth — $CRBU +175% premarket, opened +30%, now flat. My take on the latest Antler data, via @ApexOnco -> https://t.co/GNYYkqjUsm $ALLO $GILD $ACLX $LEGN↗
August 2025 · 1 mention
Aug 4
Jacob Plieth — Who's been around long enough to remember why $ALLO ALLO-647 was even a thing? $CLLS↗